Regional $^{18}$F-fluoromisonidazole PET images generated from multiple advanced MR images using neural networks in glioblastoma

Jianhua Qin, MD$^{a,b}$, Yu Tang, MD$^b$, Bao Wang, MD$^c$,*

Abstract
Generated $^{18}$F-fluoromisonidazole ($^{18}$F-FMISO) positron emission tomography (PET) images for glioblastoma are highly sought after because $^{18}$F-FMISO can be radioactive, and the imaging procedure is not easy. This study aimed to explore the feasibility of using advanced magnetic resonance (MR) images to generate regional $^{18}$F-FMISO PET images and its predictive value for survival.

Twelve kinds of advanced MR images of 28 patients from The Cancer Imaging Archive were processed. Voxel-by-voxel correlation analysis between $^{18}$F-FMISO images and advanced MR images was performed to select the MR images for generating regional $^{18}$F-FMISO images. Neural network algorithms provided by the MATLAB toolbox were used to generate regional $^{18}$F-FMISO images. The mean square error (MSE) was used to evaluate the regression effect. The prognostic value of generated $^{18}$F-FMISO images was evaluated by the Mantel-Cox test.

A total of 299,831 voxels were extracted from the segmented regions of all patients. Eleven kinds of advanced MR images were selected to generate $^{18}$F-FMISO images. The best neural network algorithm was Bayesian regularization. The MSEs of the training, validation, and testing groups were 2.92E-2, 2.9E-2, and 2.92E-2, respectively. Both the maximum Tissue/Blood ratio ($P = .017$) and hypoxic volume ($P = .023$) of the generated images were predictive factors of overall survival, but only hypoxic volume ($P = .029$) was a predictive factor of progression-free survival.

Multiple advanced MR images are feasible to generate qualified regional $^{18}$F-FMISO PET images using neural networks. The generated images also have predictive value in the prognostic evaluation of glioblastoma.

Abbreviations: $^{18}$F-FMISO = $^{18}$F-fluoromisonidazole, GBM = glioblastoma multiforme, HV = hypoxic volume, MSE = mean square error, OS = overall survival, PET = positron emission tomography, PFS = progression-free survival, T/B = tissue-to-blood ratio, TB$_{max}$ = maximum tissue-to-blood ratio.

Keywords: $^{18}$F-FMISO, glioblastoma, hypoxia, MRI, neural network

1. Introduction
Glioblastoma multiforme (GBM) is the most malignant primary tumor of the brain, with a high mortality and poor prognosis.[1] Radiation treatment is a common therapy for GBM patients after surgical resection. However, many patients did not benefit from the treatment because of radiation resistance of GBM. Hypoxia plays a vital role in radiation resistance.[2]

The strategy of radiation therapy could be improved by the identification of hypoxic subregions of GBM because a higher radiation dose could be delivered to the hypoxic subregions to overcome radiation resistance.[3] Noninvasive and reliable hypoxic imaging has always been treated as an appropriate approach to evaluate the hypoxic conditions of tumors.[4] $^{18}$F-Fluoromisonidazole ($^{18}$F-FMISO) is a positron emission tomography (PET) imaging agent that selectively binds to hypoxic tissues. $^{18}$F-FMISO uptake has been investigated because of correlation with polarographic oxygen electrodes, which is the gold standard in evaluating hypoxia.[5] Previous studies have confirmed the value of $^{18}$F-FMISO PET in evaluating hypoxic conditions and prognosis in GBM.[6,7]

Although $^{18}$F-FMISO PET is quite helpful in identifying the hypoxic region, the radioactivity of PET examination cannot be avoided.[4] In addition, preparation of $^{18}$F-FMISO was not easy, and patient blood should be collected to investigate the average blood activity to produce a pixel-level tissue-to-blood ratio.[7] These disadvantages may restrict the widespread use of $^{18}$F-FMISO PET in clinical practice. Generating images giving the same information as $^{18}$F-FMISO PET images with other non-radioactive imaging methods with easy accessibility is always desired and meaningful. Dynamic contrast-enhanced perfusion-weighted imaging (DCE-PWI) and dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) could reflect the permeability and hemodynamic characteristics of abnormal
2. Materials and Methods

2.1. Study population

All imaging and clinical data were collected from the ACRIN-FMISO-Brain dataset in the Cancer Imaging Archive. According to the description of the dataset, the patients in this dataset had some residual tumor (as determined by the treating physician) after surgery but before radiotherapy and chemotherapy, based on postcontrast T1WI or T2 fluid-attenuated inversion recovery (T2-FLAIR) imaging, although the minimum amount was not specified. Of the 45 patients in the ACRIN-FMISO-Brain dataset, 17 patients were excluded because of no evaluable 18F-FMISO PET scans or advanced MR images. Finally, 28 patients with 33 scans were included in this study. Figure 1 demonstrates how sample size was derived. The summarized clinical characteristics of the study population are provided in Table 1. The workflow of this study is provided in the Supplementary Files, http://links.lww.com/MD/G930.

This retrospective study received approval from the hospital’s ethical committee. Written informed consent was not required for this study because the data were acquired from The Cancer Imaging Archive. All experiments were performed in compliance with the Declaration of Helsinki.

2.2. MR examination and image acquisition

MR imaging (MRI) and 18F-FMISO PET were performed separately during a small interval. All sites followed a standardized acquisition protocol for these scans. (e.g., see http://www.acrin.org/Portals/0/Protocols/6684/ACRIN6684_Amend7_012412_master_ForOnline.pdf for full details). Only MRI data consisting of precontrast T1WI, T2-FLAIR images, T1 mapping, DSC-PWI, DCE-PWI, DTI, and postcontrast T1WI were used in this study.

2.3. Generation of Quantitative MR images

First, T1 mapping, DSC-PWI, DCE-PWI, and DTI were used to generate advanced MR images. All the raw data were transferred to dedicated workstations, and postprocessing was performed with commercial software (NordicIC, version 4.0.6; NordicNeuroLab, Bergen, Norway) by an experienced neuroradiologist (over 15 years). Detailed processing information is provided in the Supplementary Files, http://links.lww.com/MD/G930.

Second, each of the generated maps was normalized by dividing the mean value of the pons. This is necessary for advanced MR images and can be considered as the normalization step in individual level. Finally, 12 kinds of normalized advanced MR images, including T1 mapping, cerebral blood flow (CBF) map, cerebral blood volume (CBV) map, contrast agent transfer constant Ktrans and Kep, vascular fraction (Vv), extravascular fraction (Ve), time to peak map, peak map, area under the curve map, ADC, and fractional anisotropy maps, were used to generate 18F-FMISO PET images.

2.4. Processing of Quantitative MR images and FMISO image

The FMISO image data should be normalized by the average blood activity to produce pixel-level tissue-to-blood ratio (T/B) values for all image slices. In addition, the twelve kinds of advanced MR images and FMISO images have a similar scale.

First, they were registered to postcontrast T1WI images in noncommercial software (ITK-SNAP, Version 3.6.0; www.itksnap.org). Then, the moving images (advanced MR maps and 18F-FMISO PET images) were resliced into the space of the postcontrast T1WI images with linear interpolation. At last, smoothing was performed on all the resliced images with a full width at half maximum of [8,8,8]. In addition, T2-FLAIR images were also processed as above steps.

2.5. Segmentation for further analysis

Segmentations were manually performed on ITK-SNAP by an experienced radiologist (over 10 years). The segmentations should cover the enhancing lesions in postcontrast T1WI (after normalization and smoothing) and high-intensity peritumoral region areas in the processed T2-FLAIR images (after normalization and smoothing). Hypoxia may be in peritumoral regions. In addition, another neuroradiologist (with >15 years of experience) confirmed the segmentations.

2.6. Training the fitting model by neural networks

Only the voxels within the segmentation were used for further analysis. The values of voxels were extracted in MATLAB (version 2020a, Mathwork, Inc., Natick, MA, USA). First, the matrix data form within the segmentation of each scan was transformed to the vector data form within a fixed arrangement principle provided by MATLAB. Second, the values of all scans were combined into a matrix dataset (the column represents the variables, and the rows represent the scans). As there are 12 kinds of advanced MR images and 1 FMISO PET image, therefore, there are 13 columns in total. Advanced MR values were treated as numeric predictors and FMISO PET value was treated as response variable. The data of each column (voxels values from the same advanced MR images) would be rescaled into 0 to 1, and it is considered as the normalization step in pixels level. Normalization at individual level and pixel level would help us improve the performance of training models. Voxel-by-voxel correlation between FMISO images and 12 advanced MR images was evaluated to explore the relationships between FMISO images and advanced MR images.

Two-layer feed-forward networks were used to train the fitting model in this study. The voxel values of 12 advanced MR images were treated as predictor data and those of FMISO images were treated as response values. The first fully connected layer of the neural network has a connection from the network input (predictor data), and each subsequent layer has a connection from the previous layer. Each fully connected layer multiplies the input by a weight matrix and then adds
a bias vector. An activation function follows each fully connected layer, excluding the last. The final fully connected layer produces the network’s output, namely predicted response values.

The dataset was transported to the Neural Net Fitting App in MATLAB, among which 70 percent, 15 percent, and 15 percent of the dataset were used for training, validation, and testing, respectively. The number of hidden neurons was 10. Three training algorithms, Levenberg-Marquardt, Bayesian regularization, and scaled conjugate gradient, were selected separately to train the data. Evaluate the model at each iteration by using the validation set. By default, the training process ends early if the validation loss is greater than or equal to the minimum validation loss computed so far, 6 times in a row. The mean square error (MSE) was used to select the best fitting algorithm. All the network computations were performed on a GPU workstation (Nvidia Tesla P4 GPU with Intel Xeon[R] central processing unit [CPU] E5-2667 v4 at 3.20). The neural network diagram is shown in Figure 1.

2.7. Analysis of generated regional FMISO image
The predicted FMISO values of each patient were in the vector data form. Therefore, to generate regional FMISO images, the vector data form was reorganized to the matrix data form within the same arrangement principle provided by MATLAB. To quantify hypoxia in each tumor region on the generated regional FMISO image, the pixel with the maximum T/B value (TBmax) and the hypoxic volume (HV) were determined. The HV was determined as the volume of pixels in the tumor ROI with a T/B ratio > 1.2. This cutoff value was previously shown to indicate significant hypoxia.[17] HV determines the spatial extent of hypoxia in a tumor, whereas TBmax reports the severity of hypoxia. Both HV and TBmax have been shown to be independent predictors of outcome in

---

**Figure 1.** Flowchart of patient inclusion and diagram of neural network. (A) Patients inclusion and exclusion. (B) Input: this layer corresponds to the predictor data. First FC layer: this layer has 10 outputs by default; ReLU activation function is applied to the first fully connected layer. Final FC layer, this layer has one output. Output, this layer corresponds to the predicted response values. N in part A represents the number of scans. DCE-PWI = dynamic contrast-enhanced perfusion-weighted imaging, DSC-PWI = dynamic susceptibility contrast perfusion-weighted imaging, FC = fully connected, FMISO = fluoromisonidazole, PET = positron emission tomography, ReLU = rectified linear unit.
brain cancer.\textsuperscript{[16]} The root mean squared error was used to evaluate the accuracy of the predicted TB\textsubscript{max} and HV.

### 2.8. Statistical analysis

Pearson correlation analysis was performed to investigate the relationship between FMISO images and 12 kinds of advanced MR images. Survival events were defined as death from any cause for overall survival (OS) and as disease progression for progression-free survival (PFS). OS was calculated from the time of histologic diagnosis of the tumor, and PFS was calculated from the time of resection to tumor progression using the Kaplan-Meier method. The prognostic values of HV and TB\textsubscript{max} were evaluated using the log-rank (Mantel-Cox) test. A P value of < .05 was considered statistically significant. For multiple tests, Bonferroni correction was used. All tests were performed using MATLAB.

### 3. Results

#### 3.1. Correlations between advanced MR images and FMISO image

In total, 299,831 voxels were extracted from all the patients, and the values of all modalities were recorded. All advanced MR images excluding K\textsubscript{ep} were significantly correlated with FMISO images (all P < .001), among which normalized CBV had the highest correlation efficiency. Therefore, K\textsubscript{ep} was not used for further image generation. The results of the correlation analysis between advanced MR images and FMISO images are shown in Table 2.

#### 3.2. Fitting performance of neural networks

The training algorithm of Bayesian regularization\textsuperscript{[18]} achieved the highest fitting performance, and the MSEs of the training, validation, and testing groups of Bayesian regularization were 2.92 × 10E-2, 2.9E-2, and 2.92E-2, respectively. The results of 3 training algorithms are summarized in Table 3. The detailed results of the Bayesian regularization algorithms are displayed in Figure 2. One case with obvious hypoxic conditions is shown in Figure 3, and another case with limited hypoxic conditions is shown in Figure 4.

#### 3.3. Accuracy of predicted TB\textsubscript{max} and HV and their prognostic value

The ground-truth value of TB\textsubscript{max} was 2.11 ± 0.79, and the predicted value of TB\textsubscript{max} was 2.09 ± 0.73. The RMSE between them was 0.077. The ground-truth value of HV was 13.18 ± 11.52, and the predicted value of HV was 13.21 ± 11.57. The root mean squared error between them was 0.054. Previous study has found that an HV value of 4.0 cc and TB\textsubscript{max} of 1.5 could be selected as the cutoff values to separate the patients into good and poor prognostic groups.\textsuperscript{[10]} The 2 groups separated by ground-truth TB\textsubscript{max} or HV were the same as those separated by predicted TB\textsubscript{max} or HV. The log-rank (Mantel-Cox) test showed that both TB\textsubscript{max} (P = .017) and HV (P = .023) were predictive factors of OS. HV (P = .029) was a predictive factor of PFS, but TB\textsubscript{max} was not (P = .064). The Log-rank (Mantel-Cox) is shown in Figure 5.

### 4. Discussion

\textsuperscript{18}F-FMISO PET is a useful but radiotoxic and inconvenient method to evaluate the hypoxic condition and prognosis of GBM. This article explored the feasibility of generating regional \textsuperscript{18}F-FMISO PET images from multiple advanced MR images via neural network fitting methods. The results showed that this non-invasive method could provide appropriate regional \textsuperscript{18}F-FMISO PET images for clinical hypoxic and prognostic evaluation.
endothelial growth factors, which further promotes aggressive and immature angiogenesis and leads to worse hypoxia. A recent animal study also confirmed the correlation between 18F-FMISO uptake and blood flow, blood volume, and the metabolic rate of oxygen, which could explain why nCBV, nCBF, and Vp had a higher correlation with the uptake of 18F-FMISO than other parameters. However, a higher cellular density means more oxygen occupation than under normal conditions, which may explain why ADC values also had a higher correlation. Other quantitative parameters with an absolute R value < 0.2 may indicate that the physiological changes associated with them play less important roles in the development of hypoxic environments.

4.2. Potential influence on treatment strategy

PET could provide functional information by visualizing the metabolism of the cell. In radiation therapy for cancer, the tumor oxygen concentration is an important factor that greatly affects the therapeutic effects. The radiation sensitivity of cells is thus reduced under hypoxic conditions below a certain oxygen concentration threshold. In addition to causing radioresistance, tumor hypoxia also interferes with the cytotoxic activities of many types of chemotherapy, a phenomenon known as chemoresistance. Evaluation of the hypoxic subregion of tumors would help adjust the treatment strategy. For example, to achieve better disease control, a higher dose of radiation would be delivered to the tumor if it had a severely hypoxic environment.

4.3. Potential influence on predicting prognosis

Gerstner et al. and Bekaert et al. reported a different predictive value of 18F-FMISO PET in PFS and OS. This difference may result from the various criteria for separating the 2 groups with different prognoses. Gerstner et al. found that only SUVmax could predict the one-year OS of patients with GBM. Bekaert et al. found that patients with no uptake of 18F-FMISO had a longer PFS and OS than those without 18F-FMISO. In this study, using the same follow-up results but a different cutoff value of TBmax and HV from Gerstner et al., we found that both TBmax and HV could be predictors of patient prognosis.
These findings may reveal the importance of the cutoff value in evaluating prognosis.

However, the ground-truth $TB_{\text{max}}$ and HV had a small variance compared to the predicted values, and the 2 prognostic groups separated by ground-truth $TB_{\text{max}}$ or HV were the same as those separated by predicted $TB_{\text{max}}$ or HV. This result indicates the validity and feasibility of the predicted $TB_{\text{max}}$ or HV. However, although controversy exists regarding the prognostic
value, the predicted TB\textsubscript{max} or HV could still provide some prognostic value to clinicians. However, whether the spatial extent of hypoxia (HV) plays a more vital role than the severity of hypoxia (TB\textsubscript{max}) when predicting prognosis still needs to be explored in a large study.

Some limitations should be addressed here. Only a limited number of patients were included in this study because we could only obtain these valuable data from the public dataset. To guarantee the training efficiency of input data under the condition of limited training data, on the one hand, instead of using image-to-image translation/generation, we used a voxel-to-voxel value regression method to achieve data augmentation; on the other hand, we made the regional part of brain images the input of machine learning to only generate regional 18F-FMISO images to improve the data quality.

In conclusion, we developed a feasible approach to generating regional 18F-FMISO images from multiple advanced MR images to evaluate the hypoxic condition and prognosis of GBM, making the process of assessing tumoral hypoxia nonradiotoxic and noninvasive, facilitating the adjustment of treatment strategy and prognosis prediction.

**Author contributions**

Guarantor of integrity of the entire study: Bao Wang
Study concepts and design: Bao Wang & Jianhua Qin
Literature research: Yu Tang
Experimental studies/data analysis: Yu Tang & Jianhua Qin

Statistical analysis: Bao Wang
Manuscript preparation: Jianhua Qin
Manuscript editing: Bao Wang

**References**

[1] Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–20.

[2] Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605–22.

[3] Noch EK, Ramakrishna R, Magge R. Challenges in the treatment of glioblastoma: multisystem mechanisms of therapeutic resistance. World Neurosurg. 2018;116:505–17.

[4] Corroyer-Dulmont A, Chakhoyan A, Collet S, et al. Imaging Modalities to Assess Oxygen Status in Glioblastoma. Front Med (Lausanne). 2015;2:57.

[5] Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417–28.

[6] Yamamoto Y, Maeda Y, Kawai N, et al. Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas. Nucl Med Commun. 2012;33:621–5.

[7] Spence AM, Muzi M, Swanson KR, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14:2623–30.

[8] Cuendó CA, Balvay D. Perfusion and vascular permeability: basic concepts and measurement in DCE-CT and DCE-MRI. Diagn Interv Imaging. 2013;94:1187–204.
[9] Barbier EL. T2*-weighted perfusion MRI. Diagn Interv Imaging. 2013;94:1205–9.
[10] Li Y, Zhang W. Quantitative evaluation of diffusion tensor imaging for clinical management of glioma. Neurosurg Rev. 2020;43:881–91.
[11] Park JE, Kim HS, Park SY, et al. Identification of early response to anti-angiogenic therapy in recurrent glioblastoma: amide proton transfer-weighted and perfusion-weighted MRI compared with diffusion-weighted MRI. Radiology. 2020;295:397–406.
[12] Wang YL, Yao J, Chakhoyan A, et al. Association between tumor acidity and hypervascularity in human gliomas using pH-weighted amine chemical exchange saturation transfer echo-planar imaging and dynamic susceptibility contrast perfusion MRI at 3T. AJNR Am J Neuroradiol. 2019;40:979–86.
[13] Stoyanova R, Huang K, Sandler K, et al. Mapping tumor hypoxia in vivo using pattern recognition of dynamic contrast-enhanced MRI Data. Transl Oncol. 2012;5:437–47.
[14] Soffer S, Ben-Cohen A, Shimon O, et al. Convolutional neural networks for radiologic images: a radiologist’s guide. Radiology. 2019;290:590–606.
[15] Rudie JD, Rauschecker AM, Bryan RN, et al. Emerging applications of artificial intelligence in neuro-oncology. Radiology. 2019;290:607–18.
[16] Muzi M, Peterson LM, O’Sullivan JN, et al. 18F-fluoromisonidazole quantification of hypoxia in human cancer patients using image-derived blood surrogate tissue reference regions. J Nucl Med. 2015;56:1223–8.
[17] Rajendran JG, Schwartz DL, O’Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435–41.
[18] Burden F, Winkler D. Bayesian regularization of neural networks. Methods Mol Biol. 2008;458:25–44.
[19] Gerstner ER, Zhang Z, Fink JR, et al. ACRIN 6684: assessment of tumor hypoxia in newly diagnosed glioblastoma using 18F-FMISO PET and MRI. Clin Cancer Res. 2016;22:5079–86.
[20] Gerstner ER, Zhang Z, Fink JR, et al. ACRIN 6684: assessment of tumor hypoxia in newly diagnosed glioblastoma using 18F-FMISO PET and MRI. Clin Cancer Res. 2016;22:5079–86.
[21] Bekaert L, Valable S, Lechapt-Zalcman E, et al. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis. Eur J Nucl Med Mol Imaging. 2017;44:1383–92.
[22] Ponte KF, Berro DH, Collet S, et al. In vivo relationship between hypoxia and angiogenesis in human glioblastoma: a multimodal imaging study. J Nucl Med. 2017;58:1574–9.
[23] Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38–47.
[24] Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8:610–22.
[25] Watabe T, Kanai Y, Ikeda H, et al. Quantitative evaluation of oxygen metabolism in the intratumoral hypoxia: [18]F-fluoromisonidazole and (15)O-labelled gases inhalation PET. EJNMMI Res. 2017;7:16.
[26] Taylor MA, Das BC, Ray SK. Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma. Apoptosis. 2018;23:563–75.